Palatin Technologies Yönetim

Yönetim kriter kontrolleri 2/4

Palatin Technologies CEO'su Carl Spana, Jun2000 tarihinde atandı, in görev süresi 24.42 yıldır. in toplam yıllık tazminatı $ 1.45M olup, şirket hissesi ve opsiyonları dahil olmak üzere 48.3% maaş ve 51.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.72% ine doğrudan sahiptir ve bu hisseler $ 154.90K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 13.9 yıl ve 19.5 yıldır.

Anahtar bilgiler

Carl Spana

İcra Kurulu Başkanı

US$1.4m

Toplam tazminat

CEO maaş yüzdesi	48.3%
CEO görev süresi	24.4yrs
CEO sahipliği	0.7%
Yönetim ortalama görev süresi	13.9yrs
Yönetim Kurulu ortalama görev süresi	19.5yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Carl Spana'un ücretlendirmesi Palatin Technologies'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$32m
Jun 30 2024	US$1m	US$700k	-US$30m
Mar 31 2024	n/a	n/a	-US$31m
Dec 31 2023	n/a	n/a	-US$32m
Sep 30 2023	n/a	n/a	-US$21m
Jun 30 2023	US$1m	US$700k	-US$24m
Mar 31 2023	n/a	n/a	-US$27m
Dec 31 2022	n/a	n/a	-US$26m
Sep 30 2022	n/a	n/a	-US$37m
Jun 30 2022	US$1m	US$640k	-US$36m
Mar 31 2022	n/a	n/a	-US$37m
Dec 31 2021	n/a	n/a	-US$35m
Sep 30 2021	n/a	n/a	-US$37m
Jun 30 2021	US$2m	US$620k	-US$34m
Mar 31 2021	n/a	n/a	-US$27m
Dec 31 2020	n/a	n/a	-US$27m
Sep 30 2020	n/a	n/a	-US$22m
Jun 30 2020	US$2m	US$600k	-US$22m
Mar 31 2020	n/a	n/a	US$37m
Dec 31 2019	n/a	n/a	US$37m
Sep 30 2019	n/a	n/a	US$37m
Jun 30 2019	US$2m	US$505k	US$36m
Mar 31 2019	n/a	n/a	-US$5m
Dec 31 2018	n/a	n/a	US$344k
Sep 30 2018	n/a	n/a	US$8m
Jun 30 2018	US$3m	US$491k	US$25m

Tazminat ve Piyasa: Carl 'nin toplam tazminatı ($USD 1.45M ), UK pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 354.57K ).

Tazminat ve Kazançlar: Carl şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Carl Spana (62 yo)

24.4yrs

Görev süresi

US$1,448,350

Tazminat

Dr. Carl Spana, Ph D., is a Co-Founder of Palatin Technologies Inc and has been its Chief Executive Officer and President since June 14, 2000. From June 1996 to June 14, 2000, Dr. Spana served as an Chief...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Carl Spana	Co-Founder	24.4yrs	US$1.45m	0.72% $ 154.9k
Stephen Wills	CFO, COO	27yrs	US$1.42m	0.66% $ 141.8k
Burns McClellan	Vice President of Investor Relations	no data	Veri yok	Veri yok
Stephen Slusher	Chief Legal Officer	no data	Veri yok	Veri yok
Michael Raizman	Chief Medical Officer	3.4yrs	Veri yok	Veri yok
James Hattersley	Senior Vice President of Business Development	3.4yrs	Veri yok	Veri yok
John Dodd	Senior Vice President of Preclinical Development	no data	Veri yok	Veri yok
Robert Jordan	Senior Vice President of Program Operations	no data	Veri yok	Veri yok

13.9yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim: 0KF3 'un yönetim ekibi deneyimli ve deneyimlidir ( 13.9 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Carl Spana	Co-Founder	28.4yrs	US$1.45m	0.72% $ 154.9k
John K. Prendergast	Independent Non-Executive Chairman	28.3yrs	US$154.81k	0.21% $ 45.0k
Arlene Morris	Independent Director	9.4yrs	US$97.87k	0.14% $ 30.3k
Robert deVeer	Independent Director	26yrs	US$112.87k	0.12% $ 25.2k
Alan Dunton	Independent Director	13.4yrs	US$112.87k	0.35% $ 74.4k
Anthony Manning	Independent Director	7.2yrs	US$97.87k	0.12% $ 25.8k
Raymond Rosen	Member of Female Sexual Dysfunction Expert Panel	19.5yrs	Veri yok	Veri yok
Michael Perelman	Member of Female Sexual Dysfunction Expert Panel	19.5yrs	Veri yok	Veri yok
J. Hull	Independent Director	19.2yrs	US$102.87k	0.14% $ 29.8k
Anita Clayton	Member of Female Sexual Dysfunction Expert Panel	no data	Veri yok	Veri yok
Leonard Derogatis	Member of Female Sexual Dysfunction Expert Panel	no data	Veri yok	Veri yok
Stanley Althof	Member of Female Sexual Dysfunction Expert Panel	no data	Veri yok	Veri yok

19.5yrs

Ortalama Görev Süresi

70yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 0KF3 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 19.5 yıldır).

Palatin Technologies Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Palatin Technologies, Inc., Annual General Meeting, Dec 12, 2024

Palatin Technologies, Inc., Annual General Meeting, Jun 27, 2024

Insufficient new directors

Palatin Technologies, Inc., Annual General Meeting, Jun 20, 2023

Insufficient new directors

Insufficient new directors

Recent updates

Palatin Technologies, Inc. Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis

First quarter 2025 earnings released: US$0.39 loss per share (vs US$0.48 loss in 1Q 2024)

Palatin Technologies, Inc. to Report Q1, 2025 Results on Nov 14, 2024

Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule Pl7737 Obesity Program at Obesityweek 2024

Palatin Technologies, Inc. Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity

Palatin Technologies, Inc. Presents Illustrates Data from Clinical and Preclinical Studies for Three Proprietary Melanocortin Agonists

Palatin Receives Notice of Non-Compliance from NYSE American

New major risk - Revenue and earnings growth

Full year 2024 earnings released: US$2.02 loss per share (vs US$2.21 loss in FY 2023)

Palatin Technologies, Inc. to Report Q4, 2024 Results on Oct 01, 2024

Palatin Technologies, Inc., Annual General Meeting, Dec 12, 2024

Palatin Technologies, Inc. Announces FDA Confirms Acceptability of Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED)

Palatin Technologies, Inc. Announces First Patient Dosed in Phase 2 Clinical Study of Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity

New major risk - Shareholder dilution

Forecast to breakeven in 2027

Palatin Technologies, Inc. Announces Initiation of Phase 2 Clinical Study of Bremelanotide Co-Administered with PDE5i for Treatment of Erectile Dysfunction

Palatin Technologies, Inc. Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity

Palatin Technologies, Inc., Annual General Meeting, Jun 27, 2024

Third quarter 2024 earnings released: US$0.53 loss per share (vs US$0.63 loss in 3Q 2023)

Palatin Technologies, Inc. to Report Q3, 2024 Results on May 15, 2024

Palatin Announces Phase 3 Pl9643 Melody-1 Dry Eye Disease (Ded) Clinical Data Results Presented At American Society of Cataract and Refractive Surgery (Ascrs) 2024

No longer forecast to breakeven

New minor risk - Profitability

Second quarter 2024 earnings released: US$0.56 loss per share (vs US$0.13 loss in 2Q 2023)

Palatin Announces Database Lock for PL9643 Melody-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)

Palatin Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $10.000006 million.

Palatin Technologies, Inc. Provides Corporate Update and Highlights Strategic Priorities for Year 2024

Forecast to breakeven in 2026

Palatin Technologies Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American

First quarter 2024 earnings released: US$0.48 loss per share (vs US$0.86 loss in 1Q 2023)

New major risk - Negative shareholders equity

Palatin Technologies, Inc. to Report Q1, 2024 Results on Nov 14, 2023

Palatin Technologies, Inc. announced that it expects to receive $5.000001 million in funding

Palatin Technoloes, Inc. Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients

Palatin Receives Notice of Non-Compliance from NYSE American

Palatin Receives Notice of Non-Compliance from NYSE American

Full year 2023 earnings released: US$2.53 loss per share (vs US$3.79 loss in FY 2022)

Palatin Technologies, Inc. to Report Q4, 2023 Results on Sep 28, 2023

Insufficient new directors

Palatin Technologies, Inc. Completes Enrollment in Phase 3 Melody-1 Study of PL9643 for the Treatment of Patients with Dry Eye Disease

Palatin Technologies, Inc. Initiates Clinical Program for Bremelanotide Co-Formulated with A Pde5i for the Treatment of Ed in Patients Non-Responsive to Pde5i Treatment

Palatin Technologies, Inc.'s Vyleesi Licensee Fosun Pharma Reports First Commercial Sale in China and South Korean Licensee Kwangdong Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study

Palatin Technologies, Inc., Annual General Meeting, Jun 20, 2023

Third quarter 2023 earnings released: US$0.63 loss per share (vs US$0.80 loss in 3Q 2022)

Palatin Technologies, Inc. to Report Q3, 2023 Results on May 16, 2023

Palatin Technologies, Inc. Presents PL8177 Ulcerative Colitis Data at Digestive Disease Week Annual Conference

Insufficient new directors

Second quarter 2023 earnings released: US$0.13 loss per share (vs US$0.91 loss in 2Q 2022)

Palatin Technologies, Inc. to Report Q2, 2023 Results on Feb 15, 2023

Insufficient new directors

Palatin Technologies Initiates Enrollment in the Phase 2 Bremelanotide BREAKOUT Study in Patients with Diabetic Kidney Disease

Frontiers in Immunology Publishes Pre-Clinical Study of Palatin's PL8177 Demonstrating Therapeutic Effects in Inflammatory Conditions

Forecast to breakeven in 2025

Insufficient new directors

Palatin Technologies, Inc. to Report Q1, 2023 Results on Nov 14, 2022

Palatin Technologies, Inc. has completed a Follow-on Equity Offering in the amount of $9.999921 million.

Palatin Technologies, Inc. Announces First Patient Has Been Enrolled in the Pl8177-205 Study with Palatin's Pl8177

Insufficient new directors

Full year 2022 earnings released: US$3.79 loss per share (vs US$3.55 loss in FY 2021)

Palatin Technologies, Inc. to Report Q4, 2022 Results on Sep 22, 2022

Palatin Announces Initiation of Patient Recruitment for Phase 2 Clinical Study Evaluating Oral PL8177 for Treatment of Ulcerative Colitis

Palatin Reports Positive Interim Analysis in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease

Palatin Technologies, Inc. Announces Appointment of Carl Spana as Chief Executive Officer Effective July 1, 2022

Insufficient new directors

Palatin Technologies, Inc., Annual General Meeting, Jun 24, 2022

Third quarter 2022 earnings released: US$0.032 loss per share (vs US$0.024 loss in 3Q 2021)

Palatin Technologies, Inc. to Report Q3, 2022 Results on May 17, 2022

Insufficient new directors

Insufficient new directors